Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT01209169 · ClinicalTrials.gov registry record
Evaluation of Novel Biomarkers From Acutely Ill Patients at Risk for Acute Kidney Injury
A clinical trial, sponsored by Astute Medical.
- Completed
- Registry status
- 890
- Enrollment target
NCT01209169: Completed study, sponsored by Astute Medical.
NCT01209169 is a clinical trial that has completed, run by Astute Medical. The registered enrollment target is 890 participants. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT01209169 has completed, sponsored by Astute Medical.
- COMPLETED
- Registry status
- 890 participants
- Enrollment target
Study Summary
The purpose of this study is to collect blood and urine samples that may help identify and validate biomarkers for the early detection and risk assessment of acute kidney injury (AKI).
Primary Outcome
Primary outcome measure: Identification and Validation of Biomarkers from Acutely ill patients at risk for AKI. (N=744) Secondary outcomes including follow-up (N=890).
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 890 participants |
| Start Date | 2010-09 |
| Est. Completion | 2013-02 |
What the finished NCT01209169 record still lists
NCT01209169 is an observational study that tracks outcomes without assigning an intervention. The registered 890 participants enrollment target is mid-sized for trials with a published cap.
The record links to 0 conditions, and to 0 interventions.
NCT01209169 does not publish any study locations in the registry export this page uses.
Frequently Asked Questions
What is clinical trial NCT01209169 about?
NCT01209169 is a clinical study titled "Evaluation of Novel Biomarkers From Acutely Ill Patients at Risk for Acute Kidney Injury". The purpose of this study is to collect blood and urine samples that may help identify and validate biomarkers for the early detection and risk assessment of acute kidney injury (AKI).
What is the current status of trial NCT01209169?
This trial is currently completed. The enrollment target is 890 participants. The study started on 2010-09. Estimated completion is 2013-02.
Who is sponsoring clinical trial NCT01209169?
This trial is sponsored by Astute Medical, which has 6 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT03564340 · 890 participants · Phase 1
Study of REGN4018 (Ubamatamab) Administered Alone or in Combination With Cemiplimab in Adult Patients With Recurrent Ovarian Cancer or Other Recurrent Mucin-16 Expressing (MUC16+) Cancers
- NCT05855200 · 892 participants · Phase 3
Study of Perioperative Dostarlimab in Participants With Untreated T4N0 or Stage III dMMR/MSI-H Resectable Colon Cancer
- NCT04862663 · 895 participants · Phase 3
Capivasertib + CDK4/6i + Fulvestrant for Advanced/Metastatic HR+/HER2- Breast Cancer (CAPItello-292)
- NCT07196748 · 882 participants · Phase 3
A Protocol of Icotrokinra Therapy in Adult and Adolescent Participants With Moderately to Severely Active Ulcerative Colitis
Similar registry start date
- NCT05988463 · started 2027-01-01 · Phase 1
Dose-Escalation Study of Artesunate Patients With IPF
- NCT07219706 · started 2026-12-10 · NA
Dietary Fiber and Time Restricted Eating
- NCT02831335 · started 2026-12-01
Technical Development of Multi-Parametric Renocerebral MRI
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia